~~<i id='E90D0BCEF6'><strike id='E90D0BCEF6'><tt id='E90D0BCEF6'><pre id='E90D0BCEF6'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-10-02 15:29:49 Page View：1457

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Summit: How researchers deal with rejection
Next article： Psychedelics group wrestles with new pharma identity

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Weight loss drugs should be covered by insurers, AMA says

MedicareisathemeattheAMAmeetingtakingplacejustsouthofWashington.BrittanyTrang/STATWASHINGTON–TheAmer

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

A letter from the executive editor: STAT UnitedHealth investigation

MikeReddyforSTATIwanttobringyourattentiontoavitallyimportant investigation STAThaspublishedtoday.For

WSS

comprehensive

comprehensive

Wikipedia

explore

A letter from the executive editor: STAT UnitedHealth investigation